DNLI vs FRMI Comparison

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Fermi Inc building a private power campus for AI-centric customers, developing and leasing large-scale, grid-independent energy generation and high-performance computing facilities purpose-built for the hyperscale era. The company is also developing a private energy and site infrastructure platform across the campus to support multiple powered shell buildings and a diversified, integrated power supply, including private power generation and delivery infrastructure, substations, internal distribution networks, water and cooling systems, and other essential infrastructure. In addition to powered shell facilities, it may offer long-term ground leases to tenants that elect to construct their own powered shell facilities on land, with or without integrated power delivery.